Objectives: Aging is associated with immunosenescence, which may alter the physiological response to trauma and influence long-term outcomes. This study aimed to compare clinical and laboratory parameters associated with in-hospital (iHM) and one-year mortality (OYM) between adult and geriatric patients with multisystem trauma and to explore laboratory findings consistent with immunosenescence in geriatric patients. Methods: In this retrospective study, 345 patients with multisystem trauma were categorized into adult (n = 255) and geriatric (n = 90) groups according to age. Clinical characteristics and laboratory parameters obtained at emergency department admission were analyzed in relation to iHM and OYM. Results: Although iHM did not differ significantly between groups (p = 0.764), OYM was significantly higher in the geriatric group (p < 0.001). In adults, iHM was associated with a higher Injury Severity Score (ISS), prolonged intensive care unit (ICU) stay, elevated white blood cell and monocyte counts, and hypoalbuminemia. OYM in adults was further associated with a higher ISS, longer hospital stays, and lower hemoglobin and hematocrit levels. In geriatric patients, iHM was associated with a higher ISS, male sex, high-energy trauma, elevated lymphocyte and creatinine levels, and lower hematological ratios. OYM in the geriatric group was additionally associated with advanced age, major surgical intervention, thrombocytopenia, elevated urea–creatinine levels, hypoalbuminemia, and lower hematological ratios. Conclusions: Despite comparable in-hospital mortality, geriatric patients with multisystem trauma demonstrated significantly higher one-year mortality. The reduced post-traumatic inflammatory response observed in geriatric patients may be indicative of underlying immunosenescence and diminished immune reserve, thus emphasizing the necessity for age-specific prognostic models in trauma care.

Objective Overactive bladder syndrome (OAB) has been defined by the International Continence Society (ICS) as feeling a sudden urge to urinate that mostly runs its course with increased daytime urination and waking up during the night to urinate. we aimed to contribute to the literature by investigating the effects of mirabegron treatment on the respiratory system in patients diagnosed with OAB. Methods The study was conducted on 63 patients diagnosed with OAB.A single dose of 50 mg tablets per day was prescribed to patients diagnosed with OAB to achieve standardization. Treatment was continued for three months. Spirometry and body plethysmography were performed to objectively evaluate the respiratory functions of patients with OAB. Results The spirometry and body plethysmography showed that the FVC value was 102.51 ± 16.99 L before, 101.77 ± 14.17 L at the first month, and 100.52 ± 15.98 L at the third month after mirabegron treatment. There was no statistically significant difference between the FVC value before mirabegron treatment and the FVC value measured at the first month after treatment, between the FVC value measured at the first month of treatment and the third month of treatment, and between the FVC values measured before treatment and the third month of treatment (p = 0.805, p = 1.000, p = 1.000, respectively). Conclusions Our study results show that mirabegron, a β3 agonist, has no negative effect on the respiratory system in patients diagnosed with overactive bladder. Keywords: β3 agonist; Mirabegron; Respiratory; Spirometry; Overactive Bladder Özet Amaç Aşırı aktif mesane sendromu (OAB), Uluslararası Kontinans Derneği (ICS) tarafından, çoğunlukla gündüz idrara çıkma ve gece idrara çıkmak için uyanma ile seyrini sürdüren ani bir idrara çıkma dürtüsü hissi olarak tanımlanmıştır. AAM tanısı alan hastalarda mirabegron tedavisinin solunum sistemi üzerine etkilerini araştırarak literatüre katkı sağlamayı amaçladık. Yöntemler Çalışma, AAM tanısı alan 63 hasta üzerinde gerçekleştirildi. AAM tanısı alan hastalara standardizasyonu sağlamak amacıyla günde tek doz 50 mg tablet reçete edildi. Tedaviye üç ay devam edildi. AAM'li hastaların solunum fonksiyonlarını objektif olarak değerlendirmek için spirometri ve vücut pletismografisi yapıldı. Bulgular Spirometri ve vücut pletismografisinde FVC değerinin mirabegron tedavisi öncesinde 102,51 ± 16,99 L, birinci ayda 101,77 ± 14,17 L, üçüncü ayda ise 100,52 ± 15,98 L olduğu görüldü. Mirabegron tedavisi öncesinde ölçülen FVC değeri ile tedavi sonrası 1. ayda ölçülen FVC değeri arasında, tedavinin 1. ayında ölçülen FVC değeri ile tedavinin 3. ayında ölçülen FVC değeri arasında ve tedavi öncesi ölçülen FVC değerleri arasında istatistiksel olarak anlamlı fark saptanmadı treatment (sırasıyla p = 0.805, p = 1.000, p = 1.000). Sonuç Çalışma sonuçlarımız, bir β3 agonisti olan mirabegron'un aşırı aktif mesane tanısı alan hastalarda solunum sistemi üzerine olumsuz bir etkisinin olmadığını göstermektedir. Anahtar Kelimeler β3 agonisti; Mirabegron; Solunum; Spirometri; Aşırı aktif mesane